Clinical Outcomes of the Borderline Resectable Pancreatic Cancer according to the Neoadjuvant Chemo-Regimens: Gemcitabine vs. FOLFIRINOX.

This study is to compare clinical outcomes including survivals between two generally used neoadjuvant chemotherapies, gemcitabine and FOLFIRINOX, for the patients with BRPC. Clinical outcomes included survival, curative resectability, and recurrence pattern survival according to chemotherapeutic regimens. B Conclusion: b FOLFIRINOX, compared to the gemcitabine regimen, provided better clinical outcomes like 2-YSR, R0 resection rate, and recur rate. [Extracted from the article]